News coverage about GenMark Diagnostics (NASDAQ:GNMK) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. GenMark Diagnostics earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 43.8035603621545 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of equities analysts have issued reports on the company. BTIG Research reiterated a “buy” rating and set a $13.00 price target on shares of GenMark Diagnostics in a research note on Thursday, August 31st. BidaskClub downgraded GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Canaccord Genuity reiterated a “buy” rating and set a $14.00 price target (down previously from $17.00) on shares of GenMark Diagnostics in a research note on Monday, August 7th. Cowen and Company reiterated an “outperform” rating and set a $17.00 price target on shares of GenMark Diagnostics in a research note on Wednesday, August 2nd. Finally, Needham & Company LLC lifted their price target on GenMark Diagnostics from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, June 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $15.00.
Shares of GenMark Diagnostics (NASDAQ:GNMK) traded up 4.24% during trading on Tuesday, hitting $9.83. The stock had a trading volume of 587,956 shares. The firm’s market cap is $537.38 million. GenMark Diagnostics has a 52-week low of $8.03 and a 52-week high of $13.67. The stock has a 50 day moving average of $10.29 and a 200 day moving average of $11.98.
GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.05). GenMark Diagnostics had a negative net margin of 111.96% and a negative return on equity of 109.89%. The firm had revenue of $12.36 million for the quarter, compared to analysts’ expectations of $12.44 million. During the same quarter in the previous year, the company earned ($0.30) EPS. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. On average, equities analysts anticipate that GenMark Diagnostics will post ($1.06) EPS for the current year.
In other news, CFO Scott Mendel sold 2,898 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $9.45, for a total transaction of $27,386.10. Following the sale, the chief financial officer now owns 138,096 shares in the company, valued at $1,305,007.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Hany Massarany sold 8,311 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $9.45, for a total transaction of $78,538.95. Following the sale, the insider now owns 372,797 shares in the company, valued at approximately $3,522,931.65. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,305 shares of company stock worth $166,717. Corporate insiders own 7.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2017/09/12/genmark-diagnostics-gnmk-earns-daily-media-sentiment-rating-of-0-14.html.
About GenMark Diagnostics
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.